Literature DB >> 26424497

Association between use of proton pump inhibitors and non-typhoidal salmonellosis identified following investigation into an outbreak of Salmonella Mikawasima in the UK, 2013.

R Freeman1, G Dabrera1, C Lane1, N Adams1, L Browning2, T Fowler3, R Gorton4, T Peters5, H Mather6, P Ashton5, T Dallman5, G Godbole5, D Tubin-Delic7, A Charlett1, I Fisher1, G K Adak1.   

Abstract

In November 2013, national public health agencies in England and Scotland identified an increase in laboratory-confirmed Salmonella Mikawasima. The role of proton pump inhibitors (PPIs) as a risk factor for salmonellosis is unclear; we therefore captured information on PPI usage as part of our outbreak investigation. We conducted a case-control study, comparing each case with two controls. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression. Thirty-nine of 61 eligible cases were included in the study. The median age of cases was 45 years; 56% were female. Of these, 33% were admitted to hospital and 31% reported taking PPIs. We identified an association between PPIs and non-typhoidal salmonellosis (aOR 8·8, 95% CI 2·0-38·3). There is increasing evidence supporting the existence of an association between salmonellosis and PPIs; however, biological studies are needed to understand the effect of PPIs in the pathogenesis of Salmonella. We recommend future outbreak studies investigate PPI usage to strengthen evidence on the relevance of PPIs in Salmonella infection. These findings should be used to support the development of guidelines for patients and prescribers on the risk of gastrointestinal infection and PPI usage.

Entities:  

Keywords:  Epidemiology; gastroenteritis; outbreaks; salmonellosis

Mesh:

Substances:

Year:  2015        PMID: 26424497     DOI: 10.1017/S0950268815002332

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  8 in total

Review 1.  Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.

Authors:  Felice Schnoll-Sussman; Philip O Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

2.  Methodology Series Module 2: Case-control Studies.

Authors:  Maninder Singh Setia
Journal:  Indian J Dermatol       Date:  2016 Mar-Apr       Impact factor: 1.494

3.  Delirium in the geriatric unit: proton-pump inhibitors and other risk factors.

Authors:  Iwona Otremba; Krzysztof Wilczyński; Jan Szewieczek
Journal:  Clin Interv Aging       Date:  2016-04-04       Impact factor: 4.458

4.  A combined case-control and molecular source attribution study of human Campylobacter infections in Germany, 2011-2014.

Authors:  Bettina M Rosner; Anika Schielke; Xavier Didelot; Friederike Kops; Janina Breidenbach; Niklas Willrich; Greta Gölz; Thomas Alter; Kerstin Stingl; Christine Josenhans; Sebastian Suerbaum; Klaus Stark
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

Review 5.  The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.

Authors:  David A Johnson; Philip O Katz; David Armstrong; Henry Cohen; Brendan C Delaney; Colin W Howden; Peter Katelaris; Radu I Tutuian; Donald O Castell
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

6.  Retrospective assessment of rapid outbreak investigation for gastrointestinal diseases using only cases and background exposure data.

Authors:  G Kafatos; P Mook; A Charlett; E Rees; R Elson; T Inns; S Kanagarajah; N J Andrews
Journal:  Epidemiol Infect       Date:  2020-02-21       Impact factor: 2.451

Review 7.  Current perspectives on invasive nontyphoidal Salmonella disease.

Authors:  Andrea H Haselbeck; Ursula Panzner; Justin Im; Stephen Baker; Christian G Meyer; Florian Marks
Journal:  Curr Opin Infect Dis       Date:  2017-10       Impact factor: 4.915

8.  Online market research panel members as controls in case-control studies to investigate gastrointestinal disease outbreaks: early experiences and lessons learnt from the UK.

Authors:  P Mook; J McCormick; S Kanagarajah; G K Adak; P Cleary; R Elson; M Gobin; J Hawker; T Inns; C Sinclair; S C M Trienekens; R Vivancos; N D McCarthy
Journal:  Epidemiol Infect       Date:  2018-01-15       Impact factor: 4.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.